{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:48Z","timestamp":1793413428328,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Key point<\/jats:title><jats:p>Considering that vaccination with the sIPV and DTaP overlap at the ages of 3 and 4 months in China, to reduce the burden of treatment on parents and increase vaccination coverage rates, we designed a postmarket clinical study of co-administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>The Sabin-strain-based inactivated poliovirus vaccine (sIPV) and the diphtheria-tetanus-acellular pertussis vaccine (DTaP) have been licensed in China for many years. To conduct a clinical study on the safety and immunogenicity of the sIPV when administered concomitantly with the DTaP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study population was divided into three groups: group 1 was the sIPV+ DTaP concomitant administration group, group 2 was the sIPV inoculation group, and group 3 was the DTaP inoculation group. Blood samples were collected prevaccination and 30 days postvaccination, and serum antibody levels were detected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study showed that the seropositive and seroconversion rates of type 1, 2 and 3 poliovirus in group 1 were higher than those in group 2, with no statistically significant difference after vaccination (P&amp;gt;0.05). Groups 1 and 3 also showed similar responses for all vaccine antigens except anti-FHA (97.65 (94.09-99.36) vs. 100 (97.89-100)). The geometric mean titers (GMTs) for the DTaP and sIPV among the groups were comparable, and the non-inferiority t test result was P&amp;lt;0.001. The number of local adverse events (AEs) reported in group 1 (29.91%) were larger than those in group 2 (12.39%) and group 3 (21.93%), among which the most common was redness. Similarly, the most common systemic AE was fever. All 5 severe AE (SAE) cases were determined by experts to be unrelated to the vaccines during the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The evidence of similar seroconversion and safety with co-administered DTaP and sIPV supports the co-administration supports the introduction of a strategy of simultaneous administration of both vaccines into routine infant immunization, and it could increase vaccination coverage and protect more infants from morbidity and mortality from these related diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04054882?term=NCT04054882&amp;amp;cntry=CN&amp;amp;draw=2&amp;amp;rank=1<\/jats:uri>, identifier NCT04054882.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.905634","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T13:27:56Z","timestamp":1658842076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity and safety of concomitant administration of the chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: A multicenter, randomized, non-inferiority, controlled trial"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenyang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2007.09.004","article-title":"Societal impact of combination vaccines: experiences of physicians, nurses, and parents","volume":"22","author":"Koslap-Petraco","year":"2008","journal-title":"J Pediatr Health Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1186\/s12879-018-3422-0","article-title":"The landscape of vaccines in China: history, classification, supply, and price","volume":"18","author":"Zheng","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw530","article-title":"Assessing the evidence for maternal pertussis immunization: a report from the bill & melinda gates foundation symposium on pertussis infant disease burden in low- and lower-middle-income countries","volume":"63","author":"Sobanjo-Ter","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.042","article-title":"Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China","volume":"38","author":"Yan","year":"2020","journal-title":"VACCINE"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.16522\/j.cnki.cjph.2018.09.016","article-title":"Analysis on the deveiopment trend and problems of combined vaccine industry in China","volume":"49","author":"Zhao","year":"2018","journal-title":"Chin J Pharm"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O'Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1086\/651611","article-title":"Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba","volume":"201","author":"Resik","year":"2010","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00237-8","article-title":"Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial","volume":"386","author":"Sutter","year":"2015","journal-title":"LANCET"},{"key":"B9","volume-title":"Guiding principles for classifification criteria of adverse events in vaccine clinical trials","year":"2015"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw433","article-title":"Phase 3 trial of a sabin strain-based inactivated poliovirus vaccine","volume":"214","author":"Liao","year":"2016","journal-title":"J Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.13200\/j.cnki.cjb.000021","article-title":"Immunogenicity and immune persistence of adsorbed diphtheria,tetanus and acellular pertussis combined vaccine","volume":"26","author":"Guang Z HL","year":"2013","journal-title":"Chin J Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1202388","article-title":"Lasting immune memory against hepatitis b in 12-13-year-old adolescents previously vaccinated with 4 doses of hexavalent DTPa-HBV-IPV\/Hib vaccine in infancy","volume":"12","author":"Behre","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2004.03.006","article-title":"Vaccines administered simultaneously: directions for new combination vaccines based on an historical review of the literature","volume":"8","author":"Fletcher","year":"2004","journal-title":"Int J Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1084451","article-title":"Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-haemophilus influenzae type b (DTPa-IPV\/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study","volume":"12","author":"Anh","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1239670","article-title":"Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and haemophilus influenzae type b conjugate vaccine (DTPa-IPV\/Hib) administered in Chinese infants","volume":"13","author":"Li","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.02.073","article-title":"Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement","volume":"39","author":"Chen","year":"2021","journal-title":"Vaccine"},{"key":"B17","volume-title":"The inactivated polio vaccine produced by China biotechnology co. LTD has been pre-certified by the world health organization","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.07.019","article-title":"Safety of pentavalent DTaP-IPV\/Hib combination vaccine in post-marketing surveillance in guangzhou, China, from 2011 to 2017","volume":"99","author":"Li","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181616180","article-title":"Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age","volume":"27","author":"Black","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.094","article-title":"Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the republic of Korea","volume":"29","author":"Lee","year":"2011","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1045-1870(03)00033-5","article-title":"Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines","volume":"14","author":"Rennels","year":"2003","journal-title":"Semin Pediatr Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1046\/j.1365-2249.2000.01306.x","article-title":"Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens","volume":"121","author":"Ryan","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(97)00224-7","article-title":"Catch-up primary vaccination with acellular pertussis vaccines in 3-4-year-old children\u2013reactogenicity and serological response","volume":"16","author":"W\u00e4rng\u00e5rd","year":"1998","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15887\/j.cnki.13-1389\/r.2014.09.002","article-title":"Observation on adverse reactions of diphtheria, tetanus and pertussis vaccination in different parts","volume":"9","author":"Lei","year":"2014","journal-title":"Chin J Clin Rational Drug Use"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.16505\/j.2095-0136.2009.06.007","article-title":"Causes and countermeasures of adverse reactions to diphtheria-pertussis-tetanus vaccination","volume":"6","author":"Xie YL","year":"2009","journal-title":"Chin J Natural Med"},{"key":"B26","article-title":"Safety and reactogenicity of DTPa-HBV-IPV\/Hib and DTPa-IPV\/I-Hib vaccines in a post-marketing surveillance setting","volume":"42","author":"Lim","year":"2011","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.08.030","article-title":"Booster vaccination with hexavalent DTPa-HBV-IPV\/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV\/Hib + HBV administered separately","volume":"23","author":"Saenger","year":"2005","journal-title":"VACCINE"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0254-6450.2011.08.017","article-title":"[Immunogenicity and safety of DTaP-IPV\/\/PRP-T combined vaccine in infants in China]","volume":"32","author":"Li","year":"2011","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial","volume":"36","author":"Chu","year":"2018","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and safety of a Sabin strain-based inactivated polio vaccine: A phase 3 clinical trial","volume":"220","author":"Hu","year":"2019","journal-title":"J Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"z380","DOI":"10.1093\/ofid\/ofz380","article-title":"Safety and immunogenicity of Sabin strain inactivated poliovirus vaccine compared with Salk strain inactivated poliovirus vaccine, in different sequential schedules with bivalent oral poliovirus vaccine: Randomized controlled noninferiority clinical trials in China","volume":"6","author":"Hu","year":"2019","journal-title":"Open Forum Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.905634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T13:28:06Z","timestamp":1658842086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.905634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2022.905634"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.905634","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"905634"}}